Cadila Healthcare has become India's second-most valuable drug company with market capitalisation of ₹54,795.82 crore, beating rivals like Lupin and Dr Reddy’s Laboratories. Cadila stock has risen 48% this year after US regulator cleared its Gujarat unit, which earlier got a warning over violation of good manufacturing practices. Notably, Sun Pharma still remains India's most valued drug firm.